INTRODUCTION AND OBJECTIVES Microvascular disease and increased platelet aggregation have been cited as contributing factors to poor wound healing and infection. Thromboelastography with platelet mapping (TEG-PM) provides a measurement of clot strength that factors in medication effects, including individual drug resistance. This may provide insight into patient-specific risk factors and an opportunity to prevent wound infections/dehiscence. This prospective, observational study aimed to determine if TEG-PM could identify patients more likely to experience postoperative wound infections/dehiscence following extremity revascularization. METHODS All patients undergoing named vessel revascularization during December 2020-August 2021 at a large tertiary institution were prospectively included. TEG-PM assays were performed on patients immediately pre-operatively and at serial intervals postoperatively up to six months. RESULTS CONCLUSIONS TEG-PM revealed a significantly higher level of platelet aggregation and clot strength (MA) with diminished platelet inhibition in patients with infection/dehiscence events following revascularization procedures, indicating that their microvascular flow may be compromised. This novel insight may expose an integral factor for at-risk patients and provide an opportunity for individualized intervention following revascularization. Microvascular disease and increased platelet aggregation have been cited as contributing factors to poor wound healing and infection. Thromboelastography with platelet mapping (TEG-PM) provides a measurement of clot strength that factors in medication effects, including individual drug resistance. This may provide insight into patient-specific risk factors and an opportunity to prevent wound infections/dehiscence. This prospective, observational study aimed to determine if TEG-PM could identify patients more likely to experience postoperative wound infections/dehiscence following extremity revascularization. All patients undergoing named vessel revascularization during December 2020-August 2021 at a large tertiary institution were prospectively included. TEG-PM assays were performed on patients immediately pre-operatively and at serial intervals postoperatively up to six months. TEG-PM revealed a significantly higher level of platelet aggregation and clot strength (MA) with diminished platelet inhibition in patients with infection/dehiscence events following revascularization procedures, indicating that their microvascular flow may be compromised. This novel insight may expose an integral factor for at-risk patients and provide an opportunity for individualized intervention following revascularization.
Read full abstract